Table 2

Baseline and post-treatment evolution of the CPT bilirubin subscore in patients with the PNPLA3 CC genotype

Baseline12 weeks after SVR24 weeks after SVR48 weeks after SVR
123123123
(A) With the PNPLA3 CC genotype
192829
254131
32122211
(B) With the PNPLA3 CG/GG genotype
112111121931
2341232331
31111
(C) With the PNPLA3 CC genotype
1211
2585854
3511321
(D) With the PNPLA3 CG/GG genotype
1111
21192162141
331212
  • (A) and (B) show the baseline and post-treatment evolution of the bilirubin component of the CPT score at 12, 24, and 48 weeks after treatment. The number in each box represents the number of patients that corresponds to that bilirubin subscore at baseline and post-treatment. The green boxes indicate improvement, whereas the orange boxes indicate worsening of the bilirubin subscore. The grey boxes indicate no change from baseline. Overall, (A) and (B) show that compared with the patients with the PNPLA3 CC genotype, those with the PNPLA3 CG/GG genotypes had slower clinical recovery (ie, higher CPT score) from higher bilirubin subscore. The first laboratory encounters 12, 24, and 48 weeks after SVR were used to calculate the bilirubin component of the CPT score.

  • (C) and (D) show the baseline and post-treatment evolution of the PSE component of the CPT score 12, 24, and 48 weeks after treatment. The number in each box represents the number of patients that corresponds to that PSE subscore at baseline and post-treatment. The green boxes indicate improvement, whereas the orange box indicates worsening of the PSE subscore. The grey boxes indicate no change from baseline. Overall, (C) and (D) show that compared with the patients with the PNPLA3 CC genotype, those with the PNPLA3 CG/GG genotypes had slower clinical recovery (ie, higher CPT score) from higher PSE subscore. The first clinical encounters 12, 24, and 48 weeks after SVR were used to calculate the PSE component of the CPT score. Patients requiring hospitalisation for PSE in the 12 weeks before the clinical encounter were assigned 3 points. Patients continuing to take any treatments for PSE including rifaximin, lactulose, or polyethylene glycol were assigned 2 points. Patients able to cease all treatments for PSE were assigned 1 point. Patients who took lactulose or polyethylene glycol for constipation but never had a diagnosis of PSE were assigned 1 point.

  • CPT, Child-Pugh; PSE, portosystemic encephalopathy; SVR, sustained virological response.